Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
europe blog main
6
×
life sciences
6
×
national blog main
national top stories
novartis
6
×
boston blog main
cancer
europe top stories
indiana blog main
indiana top stories
national
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
clinical trials
covid-19
deals
fda
startups
unity biotechnology
alzheimer's disease
What
bio
roundup
medicines
acquisitions
cancer
ceo
covid
daniel
drug
fda
gilead
ipo
o’day
sciences
therapy
abbvie’s
access
activity
address
advanced
ahead
announced
approval
approvals
approves
biggest
biofourmis
biogen
blueprint
bucks
build
buy
capacity
car
carries
celebrate
cell
certain
chance
clamped
Language
unset
6
×
Current search:
unset
×
novartis
×
" life sciences "
×
" europe blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019